Senators Target Prediction Markets on Clinical Trials and FDA Approvals Over Insider Trading and Patient Safety Fears

rifanmuazin - Sunday, November 22, 2026 | 13:36
Finance Poetry
Senators Target Prediction Markets on Clinical Trials and FDA Approvals Over Insider Trading and Patient Safety Fears

WASHINGTON — The rising popularity of prediction market event contracts tied to sensitive healthcare milestones—including clinical drug trials and Food and Drug Administration regulatory decisions—has officially triggered a sharp legislative pushback. According to a letter obtained first by CNBC, two prominent Democratic senators are demanding answers from federal health officials regarding the potential risks these speculative financial instruments pose to public health, scientific integrity, and regulatory oversight.

Sen. Angela Alsobrooks, D-Md., and Sen. Ron Wyden, D-Ore., formally raised their concerns in a Wednesday letter addressed to Department of Health and Human Services Secretary Robert F. Kennedy Jr. In their correspondence, the lawmakers pressed the agency to disclose what measures, if any, the HHS has taken to mitigate the myriad risks that may arise as commercial prediction platforms allow everyday users to wager on the success or failure of experimental medicines.

The lawmakers argued that financial speculation on medical research strikes at the foundational credibility of modern medicine. "Allowing individuals to bet on the success of these trials and drugs undermines the scientific process, creates perverse incentives for researchers, harms trial participants, and could lead to dangerous medical outcomes for untold numbers of Americans," Alsobrooks and Wyden wrote in the letter.

The congressional inquiry underscores a broader, ongoing debate among lawmakers, financial regulators, and healthcare professionals regarding the rapid expansion of event-contract platforms. Both Alsobrooks and Wyden amplified warnings previously voiced by various healthcare professionals who fear that the introduction of high-stakes financial betting could subtly alter patient thinking and behavior. Specifically, medical experts worry that financial incentives or broader public sentiment surrounding trial outcomes could influence vulnerable patients when they are considering whether to volunteer for clinical trials.

Furthermore, the senators spotlighted severe insider trading risks. Regulators, academic researchers, and pharmaceutical industry insiders often possess nonpublic, material information regarding the efficacy and safety of drugs undergoing review long before those findings are made public. The existence of liquid prediction markets creates a tempting vehicle for individuals with privileged access to monetize confidential data improperly.

Communication request

To better understand the scope of the issue, the senators requested that the HHS provide all internal communications concerning staff participation in prediction markets tied to matters governed by the department. Additionally, the lawmakers demanded copies of all correspondence between the department and the prediction market platforms themselves, as well as any communications with the Commodity Futures Trading Commission, which holds regulatory authority over event contracts. They also asked for any internal analyses conducted by the agency regarding the potential impact of these markets on public health governance.

"HHS, FDA, and the National Institutes of Health must uphold the integrity of the drug development process and maintain public trust in the public health by putting essential guardrails in place to prevent individuals profiting on the success and approval of drugs that the American people depend on," Alsobrooks and Wyden emphasized in their letter.

The controversy centers on products currently offered by leading prediction market platforms, notably Kalshi and Polymarket. While Kalshi operates as a federally regulated exchange within the United States, Polymarket offers similar contracts exclusively through its international exchange, which is not regulated domestically.

When Kalshi launched its biotech prediction markets in July, the company defended the move by highlighting a series of built-in guardrails designed to minimize trading risks. These measures included restricting markets strictly to late-stage clinical trials, listing contracts only after a given trial has successfully completed patient enrollment, and implementing rigorous employee verification technology for all traders engaging with the platform.

Defending the utility of these markets at the time of their launch, Kalshi CEO Tarek Mansour argued that the pharmaceutical sector is uniquely opaque. "Drug development is one of the most important and most information-constrained industries on earth," Mansour said in July. "The data that determines which drugs advance and which don’t is largely locked away from the people who need it most. Surfacing information is what Kalshi is for, and we are committed to doing it right."

Kalshi representatives also pushed back against the premise that prediction markets present unique dangers compared to traditional financial vehicles. The company noted that investors routinely buy and sell shares in publicly traded biotechnology and pharmaceutical companies that are actively awaiting major regulatory approvals from the FDA.

"The hypothetical concerns of the Senators apply equally to the equities market, which appears to be left out of their letter," Kalshi spokesperson Jack Such told CNBC. "The only difference is that the size — and incentive for bad activity — is significantly higher in the equities market than it is on Kalshi."

Representatives for Polymarket and the Department of Health and Human Services did not immediately respond to requests for comment from CNBC regarding the senators’ letter and the ongoing scrutiny surrounding healthcare event contracts.

Source : Finance Poetry
Author : rifanmuazin
Editor : Finance Poetry Editorial Team